Cue Biopharma, Inc.
CUE
$30.44
$1.364.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,292.26% | -35.58% | 11.14% | -75.48% | -13.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,292.26% | -35.58% | 11.14% | -75.48% | -13.45% |
| Cost of Revenue | 149.56% | -51.02% | -17.00% | -17.77% | -52.67% |
| Gross Profit | 225.00% | 61.03% | 27.88% | 4.70% | 58.79% |
| SG&A Expenses | -15.95% | 47.04% | 4.78% | -0.26% | 139.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.35% | -20.86% | -11.13% | -11.57% | -27.69% |
| Operating Income | 120.33% | 15.35% | 16.84% | 2.91% | 29.59% |
| Income Before Tax | 121.96% | 14.00% | 16.61% | 0.73% | 29.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 116.69% | 14.00% | 16.61% | 0.73% | 29.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 116.69% | 14.00% | 16.61% | 0.73% | 29.31% |
| EBIT | 120.33% | 15.35% | 16.84% | 2.91% | 29.59% |
| EBITDA | 127.66% | 15.29% | 17.00% | 2.95% | 29.72% |
| EPS Basic | 111.47% | 56.32% | 56.14% | 33.85% | 55.06% |
| Normalized Basic EPS | 114.95% | 57.10% | 56.20% | 33.85% | 54.55% |
| EPS Diluted | 111.21% | 56.32% | 56.14% | 33.85% | 55.06% |
| Normalized Diluted EPS | 114.62% | 57.10% | 56.20% | 33.85% | 54.55% |
| Average Basic Shares Outstanding | 45.46% | 96.89% | 90.25% | 50.11% | 57.30% |
| Average Diluted Shares Outstanding | 48.86% | 96.89% | 90.25% | 50.11% | 57.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |